Piper Jaffray Downgrades Valeant Pharmaceuticals (VRX) to Neutral
VRX Hot Sheet
Rating Summary:6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Piper Jaffray downgraded Valeant Pharmaceuticals (NYSE: VRX) from Overweight to Neutral, price target maintained at $54.00.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $50.72 yesterday, with a 52 week range of $32.05-$57.24.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $50.72 yesterday, with a 52 week range of $32.05-$57.24.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal
- Valeant Pharma (VRX) Will Buy Swiss Herbal Remedies
- Goldman Sachs Boosts Numbers on PVH Corp (PVH) After Q1 Beat
Create E-mail Alert Related Categories
DowngradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
